NEVVI Medicare utilization intelligence
+ Build a code basket
Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS
Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg HCPCS · Chemotherapy treatment
Classification Treatment Chemotherapy Chemotherapeutic Agent (CMS RBCS)
First observed 2020
National scale 45,152 services ▲ 225.3% YoY · 239 beneficiaries (CY2024, Medicare FFS)
Medicare paid $1.9M · $41.20 avg / service, national
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window
Billing groups
8
Named-group FFS services
35,310
FFS of Medicare
49%
Services YoY
+225.3%
FFS enrollment -2.2%
Estimated all-Medicare volume FFS + estimated MA estimate
~60,948 services

35,310 observed fee-for-service (58%) · ~25,638 estimated Medicare Advantage. Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale

Top states — Q5114 (CY2024)

Disclosed Medicare fee-for-service services by billing state; open a bar for that state's ranked market.

Named-group submitted charges
$6.8M
Named-group allowed amount
$1.9M
Named-group Medicare payments
$1.5M
Avg charge / svc
$194
Avg allowed / svc
$53
Avg payment / svc
$42
Average charge per group
$97 8 groups · avg submitted charge / service $245
Market analyticsPlatform
a taste of the twelve-year trend layer

Or just look at it: nuclear heart imaging (78452) in Arizona is open as a live example — the full paid view, real data.

View the live example →

Nevvi's market analytics platform — code baskets, market structure and share, the twelve-year trend layer — is built and not launched yet. We're gathering interest in it.

Notify me at launch →
Refine: practice size any 5+ 25+ 100+ independent only
Filter results:

Email me this CSV

Data year: CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Physician groups ranked by Q5114 services, highest first, CY2024
# Physician group activate to sort City activate to sort St activate to sort Specialty activate to sort Providers activate to sort Q5114 svcs sorted descending — activate to reverse Submitted charges activate to sort Avg charge activate to sort Medicare $ locked column Share* activate to sort Phone
1 CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC LITTLE ROCK AR HEMATOLOGY/ONCOLOGY 90 9,308 $2,034,560 $219 premium 91.5%
2 GREATER BALTIMORE MEDICAL CENTER INC BALTIMORE MD HOSPITALIST 348 5,428 $529,046 $97 premium 100.0%
3 JACKSON ONCOLOGY ASSOCIATES JACKSON MS HEMATOLOGY/ONCOLOGY 11 5,063 $1,240,435 $245 premium 100.0% (601) 974-5600
4 FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC FORT MYERS IL HEMATOLOGY/ONCOLOGY 437 4,492 $1,051,128 $234 premium 100.0% (239) 561-9622
5 STATE UNIVERSITY OF IOWA IOWA CITY IA PHYSICIAN ASSISTANT 1902 4,333 $649,950 $150 premium 61.7% (319) 678-8201
6 CANCER CARE NORTHWEST CENTERS P S SPOKANE WA RADIATION ONCOLOGY 41 2,807 $624,670 $223 premium 100.0% (509) 228-1000
7 FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC FORT MYERS FL HEMATOLOGY/ONCOLOGY 437 1,605 $375,570 $234 premium 100.0% (239) 561-9622
8 SOUTH CAROLINA ONCOLOGY ASSOC PA COLUMBIA SC HEMATOLOGY/ONCOLOGY 18 1,413 $157,110 $111 premium 100.0% (803) 461-3000
9 HIGHLANDS ONCOLOGY GROUP PA FAYETTEVILLE AR NURSE PRACTITIONER 79 861 $172,200 $200 premium 8.5% (479) 361-2585

*Share of the state's disclosed Medicare-FFS services for the primary code, counted once per clinician. "St" is the state the volume was billed from: a group appears in each state where its clinicians bill Medicare, with that state's volume and share ("City" is the group's registered location). Group figures sum clinicians affiliated with exactly one group; clinicians in several groups are listed in each group's drill-down but not volume-attributed to any single group, so shares reflect attributable volume. See Methods.

Comparing against an all-payer estimate?

These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix. Modeled all-payer databases project the remainder statistically; we publish the audited floor and label it as such. Same market, different denominator. How the numbers reconcile →